Results 11 to 20 of about 30,955 (215)
Pipeline therapies for neovascular age related macular degeneration [PDF]
International Journal of Retina and Vitreous, 2021 Age related macular degeneration (AMD) is the most common cause of vision loss in the elderly population. Neovascular AMD comprises 10% of all cases and can lead to devastating visual loss due to choroidal neovascularization (CNV).
Sruthi Arepalli, Peter K. Kaiser
doaj +3 more sources
Rhizobium radiobacter Endophthalmitis following Intravitreal Ranibizumab Injection [PDF]
Case Reports in Ophthalmology, 2012 We present the first reported case of acute endophthalmitis due to Rhizobium radiobacter after an intravitreal injection of ranibizumab for neovascular age-related macular degeneration.
Lavnish Joshi +4 more
doaj +3 more sources
Photodynamic therapy for neovascular age-related macular degeneration
Philippine Journal of Ophthalmology, 2005 Background: In neovascular age-related macular degeneration (ARMD) new vessels grow under the retina, distorting vision and leading to scarring. This is exacerbated if the blood vessels leak.
Richard P.L. Wormald, MA, MB, BCh, MSc, FRCS, FRCOphth +3 more
doaj +3 more sources
Health Technology Assessment, 2022 Background: Neovascular age-related macular degeneration is a leading cause of sight loss, and early detection and treatment is important. For patients with neovascular age-related macular degeneration in one eye, it is usual practice to monitor the ...
Katie Banister +11 more
doaj +1 more source
Pegaptanib for neovascular age-related macular degeneration [PDF]
American Journal of Ophthalmology, 2004 Pegaptanib, an anti-vascular endothelial growth factor therapy, was evaluated in the treatment of neovascular age-related macular degeneration.We conducted two concurrent, prospective, randomized, double-blind, multicenter, dose-ranging, controlled clinical trials using broad entry criteria.
Gragoudas, E.S. +6 more
openaire +3 more sources
Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. [PDF]
PLoS ONE, 2014 Intravitreal injections of anti-vascular endothelial growth factor agents, such as ranibizumab, have significantly improved the management of neovascular age-related macular degeneration. This study used patient-level simulation modelling to estimate the
Paul Mitchell +9 more
doaj +1 more source
Novel approach to antiangiogenic factors in age-related macular degeneration therapy
Central European Journal of Immunology, 2022 Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss among the population above 85 worldwide. There are two main types of AMD: neovascular and dry AMD.
Katarzyna Samelska +4 more
doaj +1 more source
Radiotherapy for neovascular age-related macular degeneration [PDF]
Cochrane Database of Systematic Reviews, 2004 Radiotherapy has been proposed as a treatment to prevent new vessel growth in people with neovascular age-related macular degeneration (AMD).The aim of this review was to examine the effects of radiotherapy on neovascular AMD.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group ...
Sivagnanavel, V +3 more
openaire +6 more sources
Bacillary Layer Detachment in Neovascular Age-Related Macular Degeneration: Case Series
Biomedicines, 2023 Purpose: This study seeks to report the clinical and multimodal imaging findings of eight eyes of seven patients with neovascular age-related macular degeneration (nAMD) who developed bacillary layer detachment (BALAD).
Filomena Palmieri +3 more
doaj +1 more source
Cost effectiveness of treatments for wet age-related macular degeneration [PDF]
, 2011 Age-related macular degeneration (AMD) is a leading cause of blindness in people aged >= 50 years. Wet AMD in particular has a major impact on patient quality of life and imposes substantial burdens on healthcare systems.
Annemans, Lieven +4 more
core +1 more source